Actuate Therapeutics Overview
Latest ROE for Actuate Therapeutics: -569.09% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-569.09%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Actuate Therapeutics's return on equity stands at -569.09%. That is below the sector sector average of -5.87%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Actuate Therapeutics sits lower the its sector benchmark (-5.87%) with a ROE of -569.09%. That is roughly 9597.3% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of -569.09% for Actuate Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Actuate Therapeutics's ROE evolved across reporting periods, while the comparison chart places ACTU next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
